AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05598749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTP-101P
Description: MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 14 Days
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Miralax
Description: Miralax is a common over-the-counter laxative and bowel cleanse
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Miralax
Description: Miralax is a common over-the-counter laxative and bowel cleanse
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antacid
Description: The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12 weeks
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MTP-101P
Description: The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12 weeks
Study NCT06503978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vancomycin
Description: Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 14 days
Study NCT04892199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.34 mg/mL
Description: Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
Study NCT04892199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide-placebo
Description: The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study.
Study NCT02279615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: 50mg of mirabegron per day will be given.
Study NCT02279615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin
Description: 0.4mg of flomax per day.
Study NCT02279615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4mg of flomax per day.
Study NCT06585085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person PA sessions
Description: Group B women will have access to a weekly program of 3 face-to-face PA sessions. The face-to-face sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. They will also be offered at one or more times depending on the number of groups. Locations and times will be specified on the online booking software. Women can only register for 3 sessions per week.
Study NCT06585085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive videoconference PA sessions
Description: Women in Group C will have access to a weekly program of 3 PA sessions via interactive videoconferencing. These sessions will have the same format as the face-to-face sessions with visualization of the APA professional, visualization of the participants (who can also choose to be masked). The PA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 3 sessions per week.
Study NCT06585085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person and by videoconference (mixed format) PA sessions.
Description: Women in Group D will have access to a weekly program of 3 mixed-format PA sessions, with 2 interactive distance learning sessions and 1 in-person session. The in-person sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. Locations and times will be specified on the online booking software. Women can only register for 1 face-to-face session per week. The other 2 sessions will be offered via interactive videoconferencing. These sessions will have the same format as the in-person sessions, with visualization of the APA professional, visualization of the participants. The APA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 2 videoconference's sessions per week.
Study NCT05568797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Description: One dose of RSVPreF3 OA vaccine administered intramuscularly.
Study NCT05568797 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA vaccine
Description: One dose of RSVPreF3 OA vaccine administered intramuscularly.
Study NCT05568797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU vaccine
Description: One dose of FLU vaccine administered intramuscularly.
Study NCT05568797 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU vaccine
Description: One dose of FLU vaccine administered intramuscularly.
Study NCT06222177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pathophysiologic evaluation
Description: High-resolution manometry and pH study
Study NCT06639997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus
Study NCT05708040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InPen Medtronic
Description: Patients with DM1 ≥ 18 years of age who initiate Inpen system.
Study NCT05708040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed 780G system
Description: Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
Study NCT05279131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1%
Description: Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
Study NCT04847583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telacebec
Description: Telacebec 100 mg tablet
Study NCT04847583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Standard of care
Description: The Standard of Care treatment and administration thereof will be determined by the Investigator
Study NCT04847583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Standard of care
Description: The Standard of Care treatment and administration thereof will be determined by the Investigator
Study NCT05281757 — intervention group
Intervention type: DEVICE
Intervention: posterior stabilization for the cervical spine
Description: The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
Study NCT06099093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyl
Description: Fluorine-labeled small molecule, via intravenous infusion per protocol.
Study NCT04974008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OST31-164
Description: Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
Study NCT04179500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: pretomanid 200 mg (once daily) for 26 weeks (with meal)
Study NCT04179500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
Study NCT04305028 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
Study NCT04305028 — intervention group
Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin 75-100 mg once daily, tablet
Study NCT04179500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
Study NCT04179500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
Study NCT05005936 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo ABUS
Study NCT05005936 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo WBUS
Study NCT06258005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PocDoc
Description: PocDoc is a digital rapid 5-marker lipid test
Study NCT04808843 — intervention group
Intervention type: DRUG
Intervention: Dienogest (BAY86-5258, Visanne)
Description: Following the physicians' decision.
Study NCT03635827 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NBTX-001 Xenon Inhaler
Description: The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
Study NCT03635827 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: extinction training (nicotine cues)
Description: extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extinction training (nicotine cues)
Description: extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: extinction training (neutral cues)
Description: extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-restricted fasting
Description: Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted fasting
Description: Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
Study NCT05947162 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Time-restricted fasting with food supplemnet
Description: Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
Study NCT04262193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
Study NCT04262193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant Placebo
Description: Suvorexant Placebo
Study NCT06404359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: There will be 2 weekly sessions of 50 minutes, always guided by a physiotherapist, with the following distribution:~1.- Warm-up: 15 minutes of global exercises of strength and resistance, focusing on the areas that are going to be worked as a priority in that session.~Strength training: 6 to 8 strength exercises of large muscle groups. The approximate duration will be 25 minutes.~3.- Cool down / cool down: Combination of breathing exercises and stretching, 10 minutes.~Monitoring with activity bracelets.
Study NCT06404359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity recommendations
Description: They will be provided with a physical activity plan to be followed on a weekly basis.
Study NCT06612528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.
Study NCT06612528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.
Study NCT05350527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation of a Web Platform
Description: Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
Study NCT05574309 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer
Description: Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
Study NCT05574309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer
Description: Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
Study NCT05574309 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GAITRite Device
Description: Walking parameter measured during a 10 m walking test with GaitRite device
Study NCT05574309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GAITRite Device
Description: Walking parameter measured during a 10 m walking test with GaitRite device
Study NCT06612528 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.
Study NCT06612528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible tube in water
Description: The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.
Study NCT06612528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible tube in water
Description: The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.
Study NCT06612528 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Flexible tube in water
Description: The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.
Study NCT02992756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Factors
Description: one dose 3-6 mL of PRP obtained by PRGF Endoret
Study NCT06404255 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stress management training
Description: Stress management training
Study NCT05525000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation
Description: The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session
Study NCT06128720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen
Study NCT06128720 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Hyperbaric Oxygen
Description: Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.
Study NCT06402461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of the breath
Description: A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy
Study NCT06402461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of sounds
Description: A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy
Study NCT06402461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audiobook control
Description: Listening to a 10 minute extract from an audiobook
Study NCT05205928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
Description: The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.